Search

everythinglearnresearchcommunity

for

Search:↓

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.

The user is experiencing hair thinning and loss at the temples, likely due to androgenetic alopecia. Suggested treatments include finasteride and minoxidil to slow hair loss and promote regrowth, with buzzing hair short as a styling option.

A 42-year-old male experienced hair regrowth using a topical treatment of finasteride, ketoconazole, and minoxidil, noticing increased hair density and reduced hair loss over a year. He plans to switch to oral finasteride and continue using topical minoxidil, with a dermatologist's guidance.

Hair loss treatments, specifically the use of Alfatradiol as an over-the-counter topical 5AR inhibitor that has been shown to be effective in stopping hair loss without side effects. Other treatments discussed include Minoxidil, finasteride and RU58841.

The user is considering switching to oral dutasteride, topical minoxidil, retinoic acid, and clobetasol for hair loss treatment, after limited regrowth with finasteride and other topicals. They are seeking a source for clobetasol, as they believe it may help with their condition.

Hair loss was triggered by a testosterone and Masteron cycle, causing scalp tension and shedding. Topical finasteride, RU58841, and oral minoxidil were used to stop shedding and improve scalp condition.

A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.

User is experiencing severe hair loss despite using finasteride for 15 months, losing 500 hairs a day and 50% density since June. Minoxidil with needling was ineffective, and RU58841 is too expensive and hard to obtain.

The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.

The user experienced hair regrowth using topical finasteride 0.1%, minoxidil 10%, and microneedling over a year, recovering about 5 years of hairline and 3 years of density. The treatment was applied to the temples and frontal area, with some recovery in the coronal area attributed to microneedling.

The user showed hair regrowth after two years using finasteride, minoxidil, micro needling, and ketoconazole shampoo, noticing significant improvement around 8-10 months without experiencing shedding. They achieved thicker hair and improved temples, allowing them to style their hair without wearing hats.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

Clascoterone lotion, being tested in Germany, is as effective as Minoxidil and Finasteride for hair loss but without serious side effects. About 400 men participated in the trials.

Minoxidil and finasteride can help regrow hair, especially in thinning areas, but restoring completely receded temples is challenging and may require a hair transplant. Some users report success with these treatments, particularly when combined with microneedling.

Exploring the idea of transplanting miniaturized hair follicles to healthier areas to potentially reverse hair loss, with concerns about DHT sensitivity and scar tissue formation. The conversation also humorously considers using mice for hair growth experiments.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A user is treating hair loss with oral finasteride, topical minoxidil, and tretinoin mixed with moisturizer for easier scalp application. They also plan to use a derma pen weekly.

Adding non-prescription topicals like alfatradiol and Zix to a standard fin/min/niz regimen may help with scalp inflammation and shedding, but their long-term effectiveness varies. Zix is recommended for reducing scalp inflammation and enhancing the effectiveness of other treatments.

The user experienced stable hairline but diffuse thinning after switching from oral finasteride to a topical solution of minoxidil and finasteride. They are concerned about the effectiveness of the topical treatment and are considering other options due to a recent decline in hair density.

A person with low-density hair likely experiencing diffuse thinning. Suggested treatments include finasteride, minoxidil, and dutasteride.

A user shared their experience with hair loss treatments, including topical minoxidil, finasteride, RU58841, and microneedling, noting significant hair regrowth except at the hairline. They plan to start oral minoxidil and switch to a combination treatment, while another user mentioned that some miniaturized hairs may not fully recover.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

The user had a hair transplant 10 months ago and sees some improvement but still has thin spots. They previously used finasteride pills and now use a topical solution of minoxidil, dutasteride, and tretinoin.

The user is concerned about potential hair thinning and has been using minoxidil and finasteride for a year, noticing some new hair growth. They recently started microneedling to improve minoxidil absorption and seek advice on applying it to the crown area.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.

The user is experiencing severe hair shedding while on finasteride and plans to start using ketoconazole shampoo to address a greasy, waxy scalp buildup. They are seeking additional advice for managing hair loss.

The user experienced hair loss and started using minoxidil (5%) and finasteride (0.5 mg daily) with inconsistent application but still saw noticeable improvements by the end of January. They use the liquid form of minoxidil.

A female user is experiencing heavy hair shedding and receding temples, possibly due to low ferritin levels. She is using oral minoxidil, iron supplements, and ketoconazole shampoo, and is hesitant to start spironolactone.

The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.